View source for CENTRO DE INMUNOLOGÍA MOLECULAR (20240279348). USE OF MONOCLONAL ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR IN THE TREATMENT OF PATIENTS WITH HYPOXEMIC ACUTE RESPIRATORY FAILURE simplified abstract

=USE OF MONOCLONAL ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR IN THE TREATMENT OF PATIENTS WITH HYPOXEMIC ACUTE RESPIRATORY FAILURE=


==Organization Name==

[[:Category:CENTRO DE INMUNOLOGÍA MOLECULAR|CENTRO DE INMUNOLOGÍA MOLECULAR]]


[[Category:CENTRO DE INMUNOLOGÍA MOLECULAR]]

==Inventor(s)==

[[:Category:Tania Crombet Ramos of Habana (CU)|Tania Crombet Ramos of Habana (CU)]][[Category:Tania Crombet Ramos of Habana (CU)]]

[[:Category:Mayra Ramos Suzarte of Habana (CU)|Mayra Ramos Suzarte of Habana (CU)]][[Category:Mayra Ramos Suzarte of Habana (CU)]]

[[:Category:Danay Saavedra Hern�ndez of Habana (CU)|Danay Saavedra Hern�ndez of Habana (CU)]][[Category:Danay Saavedra Hern�ndez of Habana (CU)]]

[[:Category:Ana Laura A�� Kour� of La Habana (CU)|Ana Laura A�� Kour� of La Habana (CU)]][[Category:Ana Laura A�� Kour� of La Habana (CU)]]

[[:Category:Rolando P�rez Rodr�guez of Habana (CU)|Rolando P�rez Rodr�guez of Habana (CU)]][[Category:Rolando P�rez Rodr�guez of Habana (CU)]]

[[:Category:Henrry D�az Londres of Habana (CU)|Henrry D�az Londres of Habana (CU)]][[Category:Henrry D�az Londres of Habana (CU)]]

[[:Category:Jorge Jim�nez Armada of Habana (CU)|Jorge Jim�nez Armada of Habana (CU)]][[Category:Jorge Jim�nez Armada of Habana (CU)]]

[[:Category:Kalet Le�n Monz�n of Habana (CU)|Kalet Le�n Monz�n of Habana (CU)]][[Category:Kalet Le�n Monz�n of Habana (CU)]]

[[:Category:Anselmo Antonio Abdo Cuza of Habana (CU)|Anselmo Antonio Abdo Cuza of Habana (CU)]][[Category:Anselmo Antonio Abdo Cuza of Habana (CU)]]

==USE OF MONOCLONAL ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR IN THE TREATMENT OF PATIENTS WITH HYPOXEMIC ACUTE RESPIRATORY FAILURE - A simplified explanation of the abstract==


This abstract first appeared for US patent application 20240279348 titled 'USE OF MONOCLONAL ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR IN THE TREATMENT OF PATIENTS WITH HYPOXEMIC ACUTE RESPIRATORY FAILURE

The present invention involves the use of monoclonal antibodies against the epidermal growth factor receptor in the treatment of diseases of infectious origin that lead to hypoxemic acute respiratory failure.

* Monoclonal antibodies target the epidermal growth factor receptor.
* Treatment is focused on diseases of infectious origin.
* The goal is to address hypoxemic acute respiratory failure.
* The innovation lies in the use of specific antibodies for targeted treatment.
* This technology has potential applications in the field of biotechnology and medicine.

Potential Applications:
- Treatment of infectious diseases leading to respiratory failure.
- Precision medicine for targeted therapy.
- Research in the field of monoclonal antibodies and infectious diseases.

Problems Solved:
- Addressing hypoxemic acute respiratory failure in infectious diseases.
- Providing targeted treatment options for specific conditions.

Benefits:
- Improved outcomes for patients with infectious diseases.
- Targeted therapy with reduced side effects.
- Advancement in the field of monoclonal antibody therapy.

Commercial Applications:
Title: "Monoclonal Antibody Therapy for Infectious Diseases"
This technology can be used in pharmaceutical companies for the development of targeted therapies for infectious diseases, potentially leading to new drug discoveries and improved patient outcomes.

Questions about Monoclonal Antibody Therapy for Infectious Diseases:
1. How do monoclonal antibodies target specific receptors in the body?
   Monoclonal antibodies are designed to bind to specific antigens on cells, such as the epidermal growth factor receptor, blocking their function and signaling pathways.
2. What are the challenges in developing monoclonal antibody therapies for infectious diseases?
   Challenges may include identifying suitable targets, optimizing antibody design, and ensuring safety and efficacy in clinical trials.


==Original Abstract Submitted==

the present invention relates to the fields of biotechnology and medicine and provides the use of monoclonal antibodies against the epidermal growth factor receptor in the treatment of diseases of infectious origin that leading to a hypoxemic acute respiratory failure.



[[Category:C07K16/28]]
[[Category:A61K39/00]]
[[Category:A61P11/00]]
[[Category:CPC_C07K16/2863]]